Here is the design of a clinical trial:

Official Title: Clinical Trial Comparing Two Electroconvulsive Therapy (ECT) Application Schemas in Ultra-resistant Schizophrenia

Included conditions:
- Schizophrenia
- Electroconvulsive Therapy

Study Armgroups:
- {'label': 'Short ECT arm', 'type': 'ACTIVE_COMPARATOR', 'description': 'In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.', 'interventionNames': ['Device: Electroconvulsive therapy']}
- {'label': 'Long ECT arm', 'type': 'ACTIVE_COMPARATOR', 'description': 'In the long arm, bitemporal ECT is administered twice a week during the first 12 weeks. Afterwards, it is administered once a week during 8 weeks. After that, the patients will have one ECT every 3 weeks during 12 weeks. Lastly, patients will receive one ECT each month during 4 months.', 'interventionNames': ['Device: Electroconvulsive therapy']}

Interventions:
- {'type': 'DEVICE', 'name': 'Electroconvulsive therapy', 'description': "Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.\n\nThe stimulation dose is determined by titration method, during the first ECT session.\n\nThe dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.\n\nFor patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg).", 'armGroupLabels': ['Long ECT arm', 'Short ECT arm']}

Primary Outcomes:
- {'measure': 'The response rate (a 30% decrease in the Positive and Negative Syndrome Scale (PANSS)) at 15th month', 'description': 'The response rate (a 30% decrease in the PANSS, ranging from 30, the minimum, to 210, the most severe score) at 15th month', 'timeFrame': 'three months after the end of the treatment (i.e. 9 and 15 months)'}

Please estimate the sample size based on the assumption: 
Alpha risk (significance level) is 0.05, power is 0.80, and the estimated dropout rate is 20%.
Sample size {14}
        The aim of this trial is to compare the response rates between short and long ECT protocols. According to the meta-analysis of Lally et al. [7], the proportion of patients with treatment-resistant schizophrenia that responds to ECT augmentation of clozapine was 61.79% (Table 1: 55/89 cases). However, the relapse following ECT cessation is very high: the relapse rate has been estimated at 62.5% by Kho et al. [18]. On the other hand, Braga et al. [19] suggested that ECT were effective as a continuation strategy to prevent relapse after an acute course of ECT. During the 6-month maintenance period, no patient presented with clinically worsening symptoms. From this literature data, we postulate that the responder rates would be 61.79% in the long ECT protocol and 23.25% in the short ECT protocol (62%âÃâ(1âââ0.625)â=â23.25%). Assuming an alpha risk of 0.05 and a power of 0.80, we estimated the need to include 25 patients per group. To overcome an estimated 20% drop-out, the required number of patients increased to 32 patients per group. As a result, the total number of participants required for the study is 64 patients.